The latest update is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation reported its consolidated financial results for the first quarter of 2025, revealing a continued loss with an operating income of negative 632 million yen. The company’s net assets decreased slightly, reflecting ongoing financial challenges, and no dividends were declared for the fiscal year. The company has not provided a financial forecast for 2025 due to uncertainties in estimating future earnings.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange, primarily focused on developing innovative therapeutic solutions. The company operates within the biopharmaceutical industry, targeting genetic disorders through its proprietary technology platforms.
Average Trading Volume: 1,943,101
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.62B
For an in-depth examination of 4883 stock, go to TipRanks’ Stock Analysis page.